Intra-arterial	intra-arterial	O	O
BCNU	bcnu	S_chemical	O
chemotherapy	chemotherapy	O	O
for	for	O	O
treatment	treatment	O	O
of	of	O	O
malignant	malignant	O	O
gliomas	gliomas	O	O
of	of	O	O
the	the	O	O
central	central	O	O
nervous	nervous	O	O
system	system	O	O
.	.	O	O

Because	because	O	O
of	of	O	O
the	the	O	O
rapid	rapid	O	O
systemic	systemic	O	O
clearance	clearance	O	O
of	of	O	O
BCNU	bcnu	S_chemical	O
(	(	O	O
1,3-bis-(2-chloroethyl)-1-nitrosourea	1,3-bis-(2-chloroethyl)-1-nitrosourea	S_chemical	O
)	)	O	O
,	,	O	O
intra-arterial	intra-arterial	O	O
administration	administration	O	O
should	should	O	O
provide	provide	O	O
a	a	O	O
substantial	substantial	O	O
advantage	advantage	O	O
over	over	O	O
intravenous	intravenous	O	O
administration	administration	O	O
for	for	O	O
the	the	O	O
treatment	treatment	O	O
of	of	O	O
malignant	malignant	O	O
gliomas	gliomas	O	O
.	.	O	O

Thirty-six	thirty-six	O	O
patients	patients	O	O
were	were	O	O
treated	treated	O	O
with	with	O	O
BCNU	bcnu	S_chemical	O
every	every	O	O
6	6	O	O
to	to	O	O
8	8	O	O
weeks	weeks	O	O
,	,	O	O
either	either	O	O
by	by	O	O
transfemoral	transfemoral	O	O
catheterization	catheterization	O	O
of	of	O	O
the	the	O	O
internal	internal	O	O
carotid	carotid	O	O
or	or	O	O
vertebral	vertebral	O	O
artery	artery	O	O
or	or	O	O
through	through	O	O
a	a	O	O
fully	fully	O	O
implantable	implantable	O	O
intracarotid	intracarotid	O	O
drug	drug	O	O
delivery	delivery	O	O
system	system	O	O
,	,	O	O
beginning	beginning	O	O
with	with	O	O
a	a	O	O
dose	dose	O	O
of	of	O	O
200	200	O	O
mg/sq	mg/sq	O	O
m	m	O	O
body	body	O	O
surface	surface	O	O
area	area	O	O
.	.	O	O

Twelve	twelve	O	O
patients	patients	O	O
with	with	O	O
Grade	grade	O	O
III	iii	O	O
or	or	O	O
IV	iv	O	O
astrocytomas	astrocytomas	O	O
were	were	O	O
treated	treated	O	O
after	after	O	O
partial	partial	O	O
resection	resection	O	O
of	of	O	O
the	the	O	O
tumor	tumor	O	S_disease
without	without	O	O
prior	prior	O	O
radiation	radiation	O	O
therapy	therapy	O	O
.	.	O	O

After	after	O	O
two	two	O	O
to	to	O	O
seven	seven	O	O
cycles	cycles	O	O
of	of	O	O
chemotherapy	chemotherapy	O	O
,	,	O	O
nine	nine	O	O
patients	patients	O	O
showed	showed	O	O
a	a	O	O
decrease	decrease	O	O
in	in	O	O
tumor	tumor	O	S_disease
size	size	O	O
and	and	O	O
surrounding	surrounding	O	O
edema	edema	O	S_disease
on	on	O	O
contrast-enhanced	contrast-enhanced	O	O
computerized	computerized	O	O
tomography	tomography	O	O
scans	scans	O	O
.	.	O	O

In	in	O	O
the	the	O	O
nine	nine	O	O
responders	responders	O	O
,	,	O	O
median	median	O	O
duration	duration	O	O
of	of	O	O
chemotherapy	chemotherapy	O	O
response	response	O	O
from	from	O	O
the	the	O	O
time	time	O	O
of	of	O	O
operation	operation	O	O
was	was	O	O
25	25	O	O
weeks	weeks	O	O
(	(	O	O
range	range	O	O
12	12	O	O
to	to	O	O
more	more	O	O
than	than	O	O
91	91	O	O
weeks	weeks	O	O
)	)	O	O
.	.	O	O

The	the	O	O
median	median	O	O
duration	duration	O	O
of	of	O	O
survival	survival	O	O
in	in	O	O
the	the	O	O
12	12	O	O
patients	patients	O	O
was	was	O	O
54	54	O	O
weeks	weeks	O	O
(	(	O	O
range	range	O	O
21	21	O	O
to	to	O	O
more	more	O	O
than	than	O	O
156	156	O	O
weeks	weeks	O	O
)	)	O	O
,	,	O	O
with	with	O	O
an	an	O	O
18-month	18-month	O	O
survival	survival	O	O
rate	rate	O	O
of	of	O	O
42	42	O	O
%	%	O	O
.	.	O	O

Twenty-four	twenty-four	O	O
patients	patients	O	O
with	with	O	O
recurrent	recurrent	O	O
Grade	grade	O	O
I	i	O	O
to	to	O	O
IV	iv	O	O
astrocytomas	astrocytomas	O	O
,	,	O	O
whose	whose	O	O
resection	resection	O	O
and	and	O	O
irradiation	irradiation	O	O
therapy	therapy	O	O
had	had	O	O
failed	failed	O	O
,	,	O	O
received	received	O	O
two	two	O	O
to	to	O	O
eight	eight	O	O
courses	courses	O	O
of	of	O	O
intra-arterial	intra-arterial	O	O
BCNU	bcnu	S_chemical	O
therapy	therapy	O	O
.	.	O	O

Seventeen	seventeen	O	O
of	of	O	O
these	these	O	O
had	had	O	O
a	a	O	O
response	response	O	O
or	or	O	O
were	were	O	O
stable	stable	O	O
for	for	O	O
a	a	O	O
median	median	O	O
of	of	O	O
20	20	O	O
weeks	weeks	O	O
(	(	O	O
range	range	O	O
6	6	O	O
to	to	O	O
more	more	O	O
than	than	O	O
66	66	O	O
weeks	weeks	O	O
)	)	O	O
.	.	O	O

The	the	O	O
catheterization	catheterization	O	O
procedure	procedure	O	O
is	is	O	O
safe	safe	O	O
,	,	O	O
with	with	O	O
no	no	O	O
immediate	immediate	O	O
complication	complication	O	O
in	in	O	O
111	111	O	O
infusions	infusions	O	O
of	of	O	O
BCNU	bcnu	S_chemical	O
.	.	O	O

A	a	O	O
delayed	delayed	O	O
complication	complication	O	O
in	in	O	O
nine	nine	O	O
patients	patients	O	O
has	has	O	O
been	been	O	O
unilateral	unilateral	O	O
loss	loss	O	O
of	of	O	O
vision	vision	O	O
secondary	secondary	O	O
to	to	O	O
a	a	O	O
retinal	retinal	O	B_disease
vasculitis	vasculitis	O	S_disease
.	.	O	O

The	the	O	O
frequency	frequency	O	O
of	of	O	O
visual	visual	O	B_disease
loss	loss	O	I_disease
decreased	decreased	O	O
after	after	O	O
the	the	O	O
concentration	concentration	O	O
of	of	O	O
the	the	O	O
ethanol	ethanol	S_chemical	O
diluent	diluent	O	O
was	was	O	O
lowered	lowered	O	O
.	.	O	O

